Novartis AG (NVS)
161.24
+9.18
(+6.04%)
USD |
NYSE |
Sep 01, 16:00
161.30
+0.06
(+0.04%)
After-Hours: 20:00
Novartis Cash and Short Term Investments (Quarterly) : 7.690B for June 30, 2026
Cash and Short Term Investments (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.690B |
| March 31, 2026 | 6.977B |
| December 31, 2025 | 11.59B |
| September 30, 2025 | 9.753B |
| June 30, 2025 | 7.000B |
| March 31, 2025 | 7.196B |
| December 31, 2024 | 13.46B |
| September 30, 2024 | 14.02B |
| June 30, 2024 | 8.435B |
| March 31, 2024 | 9.751B |
| December 31, 2023 | 14.43B |
| September 30, 2023 | 12.70B |
| June 30, 2023 | 11.17B |
| March 31, 2023 | 12.26B |
| December 31, 2022 | 18.93B |
| September 30, 2022 | 19.10B |
| June 30, 2022 | 19.76B |
| March 31, 2022 | 18.81B |
| December 31, 2021 | 28.33B |
| September 30, 2021 | 8.162B |
| June 30, 2021 | 5.356B |
| March 31, 2021 | 4.077B |
| December 31, 2020 | 11.56B |
| September 30, 2020 | 10.87B |
| June 30, 2020 | 6.293B |
| Date | Value |
|---|---|
| March 31, 2020 | 4.973B |
| December 31, 2019 | 11.45B |
| September 30, 2019 | 8.717B |
| June 30, 2019 | 10.34B |
| March 31, 2019 | 7.112B |
| December 31, 2018 | 15.95B |
| September 30, 2018 | 14.71B |
| June 30, 2018 | 13.15B |
| March 31, 2018 | 6.422B |
| December 31, 2017 | 9.485B |
| September 30, 2017 | 9.421B |
| June 30, 2017 | 8.437B |
| March 31, 2017 | 8.237B |
| December 31, 2016 | 7.777B |
| September 30, 2016 | 7.785B |
| June 30, 2016 | 5.74B |
| March 31, 2016 | 5.086B |
| December 31, 2015 | 5.447B |
| September 30, 2015 | 6.064B |
| June 30, 2015 | 5.875B |
| March 31, 2015 | 7.363B |
| December 31, 2014 | 13.86B |
| September 30, 2014 | 10.43B |
| June 30, 2014 | 7.335B |
| March 31, 2014 | 7.721B |
Cash and Short Term Investments Definition
Represents the sum of cash and short term investments.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Roche Holding AG | -- |
| AstraZeneca PLC | 7.675B |
| Johnson & Johnson | 20.76B |
| Eli Lilly & Co. | 8.95B |
| Merck & Co., Inc. | 7.182B |